drugset / Trial / NCT06468358
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2
Recruiting
194 enrolled
L & L Bio Co., Ltd., Ningbo, China
Shanghai East Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2024-06-19
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB1410 | Unknown | — | Intravenous |
| Subject | LB4330 | Protein / enzyme biologic | — | Intravenous |